Pacific Biosciences of California (PACB) Expected to Announce Earnings on Thursday

Pacific Biosciences of California (NASDAQ:PACB) is projected to announce its Q4 2025 results after the market closes on Thursday, February 12th. Analysts expect Pacific Biosciences of California to post earnings of ($0.19) per share and revenue of $44.60 million for the quarter. Individuals may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, February 12, 2026 at 5:00 PM ET.

Pacific Biosciences of California (NASDAQ:PACB) last announced its quarterly earnings results on Wednesday, November 5th. The biotechnology company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.04. The business had revenue of $38.44 million during the quarter, compared to analysts’ expectations of $40.25 million. Pacific Biosciences of California had a negative net margin of 325.02% and a negative return on equity of 101.49%. On average, analysts expect Pacific Biosciences of California to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Pacific Biosciences of California Stock Performance

Shares of NASDAQ:PACB opened at $1.95 on Thursday. The company has a current ratio of 6.24, a quick ratio of 5.40 and a debt-to-equity ratio of 17.88. The company has a 50-day moving average price of $2.15 and a 200-day moving average price of $1.76. The company has a market cap of $588.72 million, a price-to-earnings ratio of -0.89 and a beta of 2.27. Pacific Biosciences of California has a 12 month low of $0.85 and a 12 month high of $2.73.

Analyst Upgrades and Downgrades

PACB has been the subject of a number of recent analyst reports. Stephens upped their price target on Pacific Biosciences of California from $1.80 to $2.00 and gave the company an “overweight” rating in a research report on Monday, November 10th. Piper Sandler upped their target price on Pacific Biosciences of California from $1.50 to $2.00 and gave the company a “neutral” rating in a report on Tuesday, November 11th. Barclays raised their price target on Pacific Biosciences of California from $1.50 to $2.00 and gave the stock an “equal weight” rating in a research note on Monday, December 15th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Pacific Biosciences of California in a research report on Thursday, January 22nd. Three research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $2.08.

Hedge Funds Weigh In On Pacific Biosciences of California

Large investors have recently made changes to their positions in the business. Creative Planning increased its stake in Pacific Biosciences of California by 245.9% during the 2nd quarter. Creative Planning now owns 175,690 shares of the biotechnology company’s stock valued at $218,000 after purchasing an additional 124,893 shares in the last quarter. Cetera Investment Advisers grew its holdings in shares of Pacific Biosciences of California by 10.1% during the second quarter. Cetera Investment Advisers now owns 104,725 shares of the biotechnology company’s stock valued at $130,000 after buying an additional 9,617 shares during the last quarter. Prudential Financial Inc. increased its position in shares of Pacific Biosciences of California by 73.0% during the second quarter. Prudential Financial Inc. now owns 35,684 shares of the biotechnology company’s stock valued at $44,000 after acquiring an additional 15,062 shares in the last quarter. Invesco Ltd. increased its position in shares of Pacific Biosciences of California by 60.0% during the second quarter. Invesco Ltd. now owns 839,340 shares of the biotechnology company’s stock valued at $1,041,000 after acquiring an additional 314,697 shares in the last quarter. Finally, HUB Investment Partners LLC purchased a new position in Pacific Biosciences of California in the 2nd quarter worth approximately $77,000.

About Pacific Biosciences of California

Pacific Biosciences of California, Inc develops, manufactures and sells high-performance DNA sequencing systems for genetic and genomic analysis. The company’s proprietary single-molecule, real-time (SMRT) sequencing technology is designed to enable long-read sequencing, offering high accuracy for applications such as de novo genome assembly, transcriptome characterization and structural variation analysis. Pacific Biosciences markets a suite of instruments, including the Sequel and Sequel IIe systems, alongside reagents, consumables and data analysis software to support a range of life science research.

Founded in 2004 and headquartered in Menlo Park, California, Pacific Biosciences has expanded its global reach by serving academic institutions, biotechnology and pharmaceutical companies, and government research centers across North America, Europe and Asia.